News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
TAIJI GP (600129.SH) Launches Global Partnership Recruitment for Semaglutide Under Development
TAIJI GP (600129.SH) stated that China National Pharmaceutical Taiji showcased its core biologic under development, semaglutide, at the Canton Fair and officially launched global p...
Reset
Send
The window will close in 5 seconds
TAIJI GP (600129.SH) Launches Global Partnership Recruitment for Semaglutide Under Development
Close
Recommend
6
Positive
5
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

TAIJI GP (600129.SH)  -0.130 (-0.838%)   stated that China National Pharmaceutical Taiji showcased its core biologic under development, semaglutide, at the Canton Fair and officially launched global partnership recruitment.

China National Pharmaceutical Taiji has established active pharmaceutical ingredient and formulation production workshops in accordance with China and US GMP requirements. The drug substance has completed US DMF filing, demonstrating mature global supply capabilities. (ta/da)(A Shares quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.